UK markets closed

Artelo Biosciences, Inc. (ARTLW)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
0.0160-0.0002 (-1.23%)
At close: 04:00PM EDT
Full screen
Loading interactive chart…
  • GlobeNewswire

    Artelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business Update

    Major achievements in 2023 lay the foundation for key upcoming milestonesSOLANA BEACH, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions, today reported financial and operating results for the fiscal year ended December 31, 2023 and provided a business update. Key Program Accomp

  • GlobeNewswire

    Artelo Biosciences Selected as a Finalist in Johnson & Johnson’s Innovation Challenge

    ART26.12 Preclinical Dermatology Research Presented to the Immuno-dermatology Leadership Team at Johnson & JohnsonSOLANA BEACH, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced its selection as a finalist in Johnson & Johnson’s (“J&J’s”; NYSE: JNJ) Innovation Challenge. Thi

  • GlobeNewswire

    Artelo Biosciences Announces Publication of New Peer-Reviewed Pre-Clinical Research Demonstrating ART26.12’s Effectiveness in Treating and Preventing Oxaliplatin-Induced Peripheral Neuropathy

    SOLANA BEACH, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced new research published in the peer-reviewed Journal of Pain. The research article, titled “Discovery and preclinical evaluation of a novel inhibitor of FABP5, ART26.12, effective in Oxaliplatin-induced Peripheral